Risks in biotech investment tend to increase as a young company gets closer and closer to its first FDA approval. Trials become more expensive, expectations......
(read more)
February 14 - News, Stock Analysis - Comments
One would think that a hepatitis B vaccine with 100% efficacy, negligible safety issues, and mountains of clinical data already supporting it would be......
(read more)
December 6 - Hedge Funds, News, Stock Analysis - Comments
No stock is ever a sure thing, but that doesn’t mean you can’t get asymptotically close to one. Following the announcement by VBI Vaccines, Inc. (......
(read more)
November 14 - News, Stock Analysis - Comments